Chlorpheniramine maleate, dextromethorphan HBr, glyceryl guaiacolate.
Each tablet contains chlorpheniramine maleate 2 mg, dextromethorphan HBr 5 mg and glyceryl guaiacolate 100 mg.
Pharmacology: Dextromethorphan HBr is a cough suppressant which reduces cough frequency. Glyceryl guaiacolate is used as an expectorant and has a sputum-thinning effect. Addition of chlorpheniramine maleate is useful in case of cough due to allergy. The sedative side effect of chlorpheniramine maleate has an advantage in the treatment of cough.
Pharmacokinetics: Following oral administration, dextromethorphan is well absorbed. The peak plasma concentration is reached 2 hrs after administration, whereas the maximum clinical effect occurs 5-6 hrs after ingestion of dextromethorphan tablets.
Dextromethorphan is extensively metabolized in the liver and the main metabolite is dextrorphan. About 50% of a dose is excreted in the urine over 24 hrs. Less than 1% of the dose is excreted in the feces. About 8% of the dose is excreted as unchanged drug in the urine in 6 hrs. It is not known if dextromethorphan or dextrorphan is excreted in breast milk or crosses the placenta.
Chlorpheniramine maleate is well absorbed after oral administration and distributed into the tissues. Chlorpheniramine maleate appears to undergo moderate first-pass metabolism and there may be an enterohepatic circulation.
Considerable intersubject variation has been found in the metabolism and excretion of chlorpheniramine maleate and the excretion was dependent on urinary pH and flow rate. About 35% of a dose was excreted as unchanged, 22% as the desmethyl metabolite and 3-10% as didesmethyl metabolite. None of the metabolites are toxic or responsible for clinical antihistaminic effect. In children, there was evidence to suggest more rapid and complete oral absorption and faster clearance.
Glyceryl guaiacolate is readily absorbed from the gastrointestinal tract, with plasma half-life of approximately 1 hr. Glyceryl guaiacolate is rapidly metabolized by oxidation to β-(2-methoxy-phenoxy)lactic acid. About 40% of a dose is excreted as metabolite in the urine in 3 hrs.
Cough due to allergy, flu, common cold and bronchitis associated with irritants.
Adults and Children ≥12 years: 1-2 tabs 3 times daily.
Children 6-12 years: ½-1 tab 3 times daily; 3-6 years: ¼-½ tab 3 times daily.
Or as directed by the physician.
Patients hypersensitive to any component of Konidin Cough Reliever Tablets. Patients who are receiving MAOI therapy.
Konidin Cough Reliever Tablets is not recommended for productive cough, pertussis, bronchial asthma or chronic cough unless directed by a physician.
Do not take higher than recommended doses.
Effects on the Ability to Drive or Operate Machinery: During Konidin Cough Reliever Tablets therapy do not drive or operate machinery.
Use in pregnancy & lactation: For pregnant women and breastfeeding mothers, it is suggested that Konidin Cough Reliever Tablets be taken with physician's direction.
Use in children: Konidin Cough Reliever Tablets is not recommended for children <2 years except under a physician's direction.
For pregnant women and breastfeeding mothers, it is suggested that Konidin Cough Reliever Tablets be taken with physician's direction.
Nausea, gastrointestinal disturbance, drowsiness.
Konidin Cough Reliever Tablets should not be taken concomitantly with MAOIs.
Store in a cool and dry place.
R05FA02 - opium derivatives and expectorants ; Belongs to the class of combinations of opium derivatives cough suppressants and expectorants. Used in the treatment of cough.